Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Shanghai Shenqi Pharmaceutical Investment Management Co's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 6.60%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
SHSE:600613's 3-Year ROIIC % is ranked better than 54.76% of 946
companies
in the Drug Manufacturers industry
Industry Median: 3.72
vs SHSE:600613: 6.60
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Shanghai Shenqi Pharmaceutical Investment Management Co 3-Year ROIIC % Related Terms
Shanghai Shenqi Pharmaceutical Investment Management Co 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Shenqi Pharmaceutical Investment Management Co 3-Year ROIIC % Chart
Shanghai Shenqi Pharmaceutical Investment Management Co Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Shenqi Pharmaceutical Investment Management Co 3-Year ROIIC % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) has a 3-Year ROIIC % of 6.60 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Shanghai Shenqi Pharmaceutical Investment Management Co and its competitors. This is 1038% above median its historical median of 0.58. According to the industry distribution chart, Shanghai Shenqi Pharmaceutical Investment Management Co ranks #428 out of 946 companies in the Drug Manufacturers industry, placing it in the top 45.2%.
Is Shanghai Shenqi Pharmaceutical Investment Management Co's 3-Year ROIIC % too high?
Shanghai Shenqi Pharmaceutical Investment Management Co's current 3-Year ROIIC % of 6.60 is 1038% above median its 10-year median of 0.58. The Drug Manufacturers industry median 3-Year ROIIC % is 3.72. Shanghai Shenqi Pharmaceutical Investment Management Co's value of 6.60 is 77.4% above this industry median. Based on the distribution chart, Shanghai Shenqi Pharmaceutical Investment Management Co ranks #428 out of 946 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Shanghai Shenqi Pharmaceutical Investment Management Co has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Shenqi Pharmaceutical Investment Management Co's 3-Year ROIIC % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Shanghai Shenqi Pharmaceutical Investment Management Co ranks #428 out of 946 companies for 3-Year ROIIC %. This puts Shanghai Shenqi Pharmaceutical Investment Management Co in the upper half of its industry. The industry median 3-Year ROIIC % is 3.72. Shanghai Shenqi Pharmaceutical Investment Management Co's value of 6.60 is 77.4% above this benchmark. While the company's 10-year median is 0.58 vs. the industry median of 3.72, Shanghai Shenqi Pharmaceutical Investment Management Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.72, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Shenqi Pharmaceutical Investment Management Co's current 3-Year ROIIC % of 6.60 is 77.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Shanghai Shenqi Pharmaceutical Investment Management Co and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Shenqi Pharmaceutical Investment Management Co's current 3-Year ROIIC % is 6.60, which is 1038% above median its own 10-year median of 0.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Shenqi Pharmaceutical Investment Management Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥5.42, compared to a current price of ¥4.74 — trading 12.5% below its estimated fair value. The current 3-Year ROIIC % is 6.60, which is 1038% above median its 10-year median of 0.58 and 77.4% above the Drug Manufacturers industry median of 3.72. Shanghai Shenqi Pharmaceutical Investment Management Co's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613), the current 3-Year ROIIC % is 6.60 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Shenqi Pharmaceutical Investment Management Co stock appears to be undervalued.
The current stock price of ¥4.74 is trading 12.5% below its estimated GF Value™ of ¥5.42.
GuruFocus considers Shanghai Shenqi Pharmaceutical Investment Management Co to be Modestly Undervalued.
Key valuation signals for SHSE:600613:
3-Year ROIIC %: 6.60 (1038% above median its 10-year median of 0.58)
GF Value™: ¥5.42 vs. price of ¥4.74 (12.5% below fair value)
Industry Position: 77.4% above the Drug Manufacturers median (#428 of 946)
No single metric tells the full story. See the SHSE:600613 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Shenqi Pharmaceutical Investment Management Co Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600613 has been successfully added to your 
